

30<sup>th</sup> April 2014

## ASX ANNOUNCEMENT

### APPENDIX 4C - QUARTERLY CASH FLOW

Analytica Limited (the Company) presents its Appendix 4C for the quarter ended 31<sup>st</sup> March 2014.

#### Cash Position

The Company had cash reserves at the end of the period of \$596k.

Research and development expenditure (\$567k), staff costs (\$33k), marketing expenses (\$134k) accounted for the bulk of the operating cash flows for the quarter. An Export Market Development Grant from Austrade of \$39k was received during the quarter.

On the 22<sup>nd</sup> April 2014, the company announced a capital raising up to \$3 million (before offer costs). Consisting of \$1.8m private placement to sophisticated investors at \$0.024 per share, and a 1 for 15 rights issue to existing investors at \$0.024.

As a result of the positive response from clinicians, directors decided to accelerate and intensify PeriCoach marketing to maximise first mover advantage. Our team are making a remarkable contribution above and beyond, and to bring timelines forward requires additional support. Additional technical team resources have been bought on board to redistribute some of this workload as well as cementing foundations for large capacity sales.

Technical and marketing projects, and production are on schedule.

The Company continues to have access to a line of credit of \$400k.

**The roll out of the PeriCoach continues on schedule.**

**Dr Michael Monsour**

Chairman, Board of Directors



*About Analytica Limited*

*Analytica's lead product is the PeriCoach™ System – an e-health treatment system for women who suffer Stress Urinary Incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles as a result of pregnancy, childbirth and menopause.*

*PeriCoach™ comprises a device, web portal and smartphone app. The device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to PeriCloud where physicians can monitor patient progress via web portal. This novel system enables physicians to remotely determine if a woman is correctly performing pelvic floor exercises and if these are improving her condition; otherwise physicians are guided on the need for surgery.*

*PeriCoach™ has been approved in Australia with product launches expected in 2014 in Australia, Europe and the US. The US market for incontinence pads is \$5 billion pa. It is projected that by 2030, 5.6 million women in Australia will suffer urinary incontinence.*

*Analytica is also commercialising the AutoStart™ Infusion System. This is a burette with improved safety and cost reduction features. It is targeting a \$3 billion pa global market, has FDA approval and potential near term cash flow with distribution agreements.*

# Appendix 4C

## Quarterly report for entities admitted on the basis of commitments

Introduced 31/3/2000. Amended 30/9/2001

Name of entity

Analytica Limited

ABN

12 006 464 866

Quarter ended ("current quarter")

31 March 2014

### Consolidated statement of cash flows

Cash flows related to operating activities	Current quarter \$A'000	Year to date (9 months) \$A'000
1.1 Receipts from customers		
1.2 Payments for		
(a) staff costs	(33)	(88)
(b) advertising and marketing	(134)	(221)
(c) research and development	(567)	(1,671)
(d) leased assets	-	-
(e) other working capital	(145)	(402)
1.3 Dividends received	-	-
1.4 Interest and other items of a similar nature received	6	13
1.5 Interest and other costs of finance paid	-	(3)
1.6 Income taxes paid	-	-
1.7 Other-		
(a) R & D Tax Concession	-	521
(b) Royalty Income	5	6
(c) Other Grant Income	39	39
<b>Net operating cash flows</b>	<b>(829)</b>	<b>(1,806)</b>

+ See chapter 19 for defined terms.

**Appendix 4C**  
**Quarterly report for entities**  
**admitted on the basis of commitments**

		Current quarter \$A'000	Year to date (9 months) \$A'000
1.8	Net operating cash flows (carried forward)	<b>(829)</b>	<b>(1,806)</b>
<b>Cash flows related to investing activities</b>			
1.9	Payment for acquisition of:		
	(a) businesses	-	-
	(b) equity investments	-	-
	(c) intellectual property	-	-
	(d) physical non-current assets	-	(4)
	(e) other non-current assets	-	-
1.10	Proceeds from disposal of:		
	(a) businesses	-	-
	(b) equity investments	-	-
	(c) intellectual property	-	-
	(d) physical non-current assets	-	-
	(e) other non-current assets	-	-
1.11	Loans to other entities	-	-
1.12	Loans repaid by other entities	-	-
1.13	Other (purchase of Convertible Notes )	-	-
	<b>Net investing cash flows</b>	-	(4)
<b>1.14</b>	<b>Total operating and investing cash flows</b>	<b>(829)</b>	<b>(1,810)</b>
<b>Cash flows related to financing activities</b>			
1.15	Proceeds from issues of shares	-	2,200
1.16	Proceeds from sale of forfeited shares	-	-
1.17	Proceeds from borrowings	-	-
1.18	Repayment of borrowings:	-	-
1.19	Dividends paid	-	-
1.20	Other Creditors (costs of fund raising)	-	(143)
	<b>Net financing cash flows</b>	-	2,057
	<b>Net increase (decrease) in cash held</b>	<b>829</b>	<b>247</b>
1.21	Cash at beginning of quarter/year to date	1,425	349
1.22	Exchange rate adjustments to item 1.20	-	-
<b>1.23</b>	<b>Cash at end of quarter</b>	<b>596</b>	<b>596</b>

+ See chapter 19 for defined terms.

**Payments to directors of the entity and associates of the directors**

**Payments to related entities of the entity and associates of the related entities**

		Current quarter \$A'000
1.24	Aggregate amount of payments to the parties included in item 1.2	48
1.25	Aggregate amount of loans to the parties included in item 1.11	-

1.26 Explanation necessary for an understanding of the transactions

Payment of director's fees and compulsory superannuation.

**Non-cash financing and investing activities**

2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

N/A

2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

N/A

**Financing facilities available**

*Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).*

		Amount available \$A'000	Amount used \$A'000
3.1	Loan facilities	400	0
3.2	Credit standby arrangements	-	-

+ See chapter 19 for defined terms.

**Reconciliation of cash**

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.	Current quarter \$A'000	Previous quarter \$A'000
4.1 Cash on hand and at bank	596	1,425
4.2 Deposits at call	-	-
4.3 Bank overdraft	-	-
4.4 Other (provide details)	-	-
<b>Total: cash at end of quarter</b> (item 1.23)	596	1,425

**Acquisitions and disposals of business entities**

	Acquisitions	Disposals
5.1 Name of entity	N/A	N/A
5.2 Place of incorporation or registration		
5.3 Consideration for acquisition or disposal		
5.4 Total net assets		
5.5 Nature of business		

**Compliance statement**

- 1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
- 2 This statement does give a true and fair view of the matters disclosed.

Sign here: [Original Signed]

Date: 30 April 2014

Print name: Ross Mangelsdorf

---

+ See chapter 19 for defined terms.